ea0050p250 | Neoplasia, Cancer and Late Effects | SFEBES2017
Abhi Dhruv
, Vennam Sarath
, Dugal Tabinda
, Edeghere Simon
Introduction: Immune checkpoint inhibitors such as CTLA 4 inhibitors (Ipilimumab) and PD1 inhibitors (Nivolumab/ Pembrolizumab) are being increasingly used for treatment of malignant melanomas and other solid tumours. Despite clinical benefits, they have been known to cause certain Immune related adverse effects (IrAEs) which may be dermatological, gastrointestinal, endocrine, or other immune phenomenon.The endocr...